Targets of the peroxisome proliferator - activated receptor γ agonist trials for the prevention of Alzheimer disease: Reply

Archives of Neurology

Volumn 68, Issue 4, 2011, Pages 542-543

  Geldmacher, David S ^a   Fritsch, Thomas ^b   Landreth, Gary E ^c  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^b AURORA SINAI MEDICAL CENTER   (United States)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; INSULIN SENSITIZING AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE;

ALZHEIMER DISEASE; CEREBROVASCULAR DISEASE; CLINICAL TRIAL (TOPIC); DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE MARKER; GENOTYPE; HUMAN; INSULIN RESISTANCE; LETTER; PRIORITY JOURNAL; RISK ASSESSMENT; TREATMENT RESPONSE;

EID: 79953875366     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneurol.2011.58     Document Type: Letter

References (5)

1. Sato T, Hanyu H, Hirao K, Kanetaka H, Sakurai H, Iwamoto T. Efficacy of PPAR-γ agonist pioglitazone in mild Alzheimer disease [published online November 16, 2009]. Neurobiol Aging. doi:10.1016/j.neurobiolaging.2009.10.009.
2. Biessels GJ, Staekenborg S, Brunner E, Brayne C, Scheltens P. Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol. 2006;5(1):64-74. (Pubitemid 41790697)
3. Middleton LE, Yaffe K. Promising strategies for the prevention of dementia. Arch Neurol. 2009;66(10):1210-1215.
4. Geldmacher DS, Fritsch T, McClendon MJ, Landreth GE. A randomized pilot clinical trial of the safety of pioglitazone in treatment of patients with Alzheimer disease. Arch Neurol. 2011;68(1):45-50.
5. Gold M, Alderton C, Zvartau-Hind M, et al. Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, doubleblind, placebo-controlled phase III study. Dement Geriatr Cogn Disord. 2010;30(2):131-146.